ZyVersa Therapeutics, Inc. · OTC:ZVSA
ZyVersa Therapeutics — Investor Presentation (2026)
18 slides from ZyVersa Therapeutics's investor presentation, 2026
Slide 1: Corporate Presentation
Corporate Presentation Corporate Presentation Restoring Health, Transforming Lives Through Innovation Q2-2026 l OTCQB: ZVSA 1
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities E
Slide 3: Key Investment Highlights
Key Investment Highlights Key Investment Highlights • Large market opportunity (> $100B TAM) across inflammatory and renal diseases including high-value orphan indications IC 100 and VAR 200 • Differentiated pipeline including a novel approach targeting ASC to inhibit the inflammasome ▪ IC 100: targ
Slide 4: Two Proprietary Product Platforms
Two Proprietary Product Platforms First-in-Class Drugs for Inflammatory and Renal Diseases Two Proprietary Product Platforms First-in-Class Drugs for Inflammatory and Renal Diseases Product Candidate Development Pre-Clinical Phase 1 Phase 2 Phase 3 Inflammasome ACS Inhibitor IC 100 Cardiometabolic (
Slide 5: Critical Unmet Need to Address Inflammation-Driven Diseases
Critical Unmet Need to Address Inflammation-Driven Diseases • Inflammation-driven diseases have become an epidemic Systemic Inflammation with increasing prevalence of obesity • Systemic inflammation is a common factor in a wide variety of disease processes • ~38 million people with type 2 diabetes1,
Slide 6: IC 100 Targets ASC/ASC Specks to Control Perpetuation of Damaging Inflammation
IC 100 Targets ASC/ASC Specks to Control Perpetuation of Damaging Inflammation Driving Innovation Across Cardiometabolic and Renal Diseases IC 100 Targets ASC/ASC Specks to Control Perpetuation of Damaging Inflammation Driving Innovation Across Cardiometabolic and Renal Diseases • Total accessible m
Slide 7: VAR 200 Targets Renal Lipids to Attenuate Renal Damage and Disease Progression
VAR 200 Targets Renal Lipids to Attenuate Renal Damage and Disease Progression Advancing Novel Therapies for FSGS and Rare Kidney Diseases VAR 200 Targets Renal Lipids to Attenuate Renal Damage and Disease Progression Advancing Novel Therapies for FSGS and Rare Kidney Diseases • Total accessible mar
Slide 8: Inflammatory Opportunity: Inflammasome ASC Inhibitor IC 100
Inflammatory Opportunity Inflammasome ASC Inhibitor: IC 100
Slide 9: Market Landscape for the Innate Immune Market: Rapidly Evolving
Market Landscape for the Innate Immune Market: Rapidly Evolving Driving Innovation Across Cardiometabolic and Renal Diseases Market Landscape for the Innate Immune Market: Rapidly Evolving Driving Innovation Across Cardiometabolic and Renal Diseases Danger signals / DAMPs / PAMPs → Inflammasome Sens
Slide 10: Critical Unmet Need to Reduce Inflammation-Driven Obesity Comorbidities
Critical Unmet Need to Reduce Inflammation-Driven Obesity Comorbidities 4 of 5 Million Annual Deaths Associated with BMI Are Related to Comorbidities1 Critical Unmet Need to Reduce Inflammation-Driven Obesity Comorbidities 4 of 5 Million Annual Deaths Associated with BMI Are Related to Comorbidities
Slide 11: IC 100 Targets the Inflammasome Through ASC Rather Than NLRP3
IC 100 Targets the Inflammasome Through ASC Rather Than NLRP3 ASC Inhibition Expected to Better Control Inflammation IC 100 Targets the Inflammasome Through ASC Rather Than NLRP3 ASC Inhibition Expected to Better Control Inflammation Potentially Inhibits 12 or More Types of Inhibits Intracellular AS
Slide 12: IC 100 Attributes Versus Key Inflammasome Competitors
IC 100 Attributes Versus Key Inflammasome Competitors IC 100 Attributes Versus Key Inflammasome Competitors IC 100 VTX 3232 VTX 2735 NT-0796 NT-0249 NN6022-0001 VENT-02 RG6418 DFV 890 Attribute (mAb) (SM) (SM) (SM) (SM) (SM) (SM) (SM) (SM) Company ZyVersa Ventyx NodThera Novo Nordisk Ventus Roche No
Slide 13: Cholesterol Efflux Mediator VAR 200
Cholesterol Efflux Mediator VAR 200
Slide 14: FSGS: A Rare Progressive Kidney Disease with No Approved Therapies
FSGS: A Rare Progressive Kidney Disease with No Approved Therapies FSGS: A Rare Progressive Kidney Disease with No Approved Therapies FSGS • Glomerular podocyte injury resulting in scarring that is focal (affects only some glomerulus) and segmental (affects only part of glomerulus) • Leads to impair
Slide 15: Renal Lipotoxicity Leads to Podocyte Structural Damage, Proteinuria, and Progression of Kidney Disease
Renal Lipotoxicity Leads to Podocyte Structural Damage, Proteinuria, and Progression of Kidney Disease1,2 Renal Lipotoxicity Leads to Podocyte Structural Damage, Proteinuria, and Progression of Kidney Disease1,2 Podocyte Lipid Distorted Podocyte Increased Susceptibility Podocyte Accumulation Structu
Slide 16: Cholesterol Efflux Mediator VAR 200 Alleviates Excess Podocyte Cholesterol and Lipids
Cholesterol Efflux Mediator VAR 200 (2-Hydroxypropyl-Beta Cyclodextrin 2HPβCD) Alleviates Excess Podocyte Cholesterol and Lipids Cholesterol Efflux Mediator VAR 200 (2-Hydroxypropyl-Beta Cyclodextrin 2HPβCD) Alleviates Excess Podocyte Cholesterol and Lipids Comprised of 7 Sugar Molecules Bound Toget
Slide 17: Comparison of FSGS Drugs in Development
Comparison of FSGS Drugs in Development Comparison of FSGS Drugs in Development Attribute ZyVersa Travere Dimerix Drug VAR 200 Sparsentan DMX-200 Molecule 2HPβCD Endothelin & Angiotensin II Receptor Chemokine Receptor (CCR2) Antagonist Antagonist MOA Cholesterol/Lipid Efflux Vasodilation Anti-inflam
Slide 18: Corporate Presentation
Corporate Presentation Corporate Presentation Restoring Health, Transforming Lives Through Innovation Q2-2026 l OTCQB:ZVSA 1